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Activation of peroxisome proliferator-activated receptors (PPARs), and particularly
of PPARα and PPARγ, using selective agonists, is currently used in the treatment of
metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus.
PPARα and PPARγ anti-inflammatory, antiproliferative and antiangiogenic
properties in cardiovascular cells were extensively clarified in a variety of in vitro
and in vivo models. In contrast, the role of PPARδ in cardiovascular system is
poorly understood. Prostacyclin, the predominant prostanoid released by vascular
cells, is a putative endogenous agonist for PPARδ, but only recently PPARδ
selective synthetic agonists were found, improving studies about the physiological
and pathophysiological roles of PPARδ activation. Recent reports suggest that the
PPARδ activation may play a pivotal role to regulate inflammation, apoptosis, and
cell proliferation, suggesting that this transcriptional factor could become an
interesting pharmacological target to regulate cardiovascular cell apoptosis,













Publié sur Okina (http://okina.univ-angers.fr)
